What does Giura Pharma do?

Giura Pharma is registered with the CBE as active in: Activiteiten van holdings. Private Limited, started on 19 March 2018, 1 establishment.

What is the address of Giura Pharma?

The registered office of Giura Pharma is located at Heidelaan 25, 2580 Putte.

Is Giura Pharma still active?

Yes. According to the CBE (30 October 2026) Giura Pharma is active, legal situation “Normale toestand”, started on 19 March 2018.

Is Giura Pharma registered on Peppol?

Yes, Giura Pharma is registered on the Peppol network with ID 0208:0692655422.

What is the enterprise number of Giura Pharma?

The enterprise number of Giura Pharma is BE0692655422.

When was Giura Pharma founded?

Giura Pharma was founded on 19 March 2018.

Who are the directors of Giura Pharma?

According to the 2025 annual accounts, the directors of Giura Pharma are: Caroline Caenepeel.

Is Giura Pharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 19 March 2018; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Giura Pharma make in 2025?

Giura Pharma posted a profit after taxes of € 81,021 in financial year 2025.

What is the revenue of Giura Pharma?

As a small company, Giura Pharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 122,490.

Giura Pharma (Private Limited) - Putte - BE0692655422

Dossier Giura Pharma, printed on 30 October 2026 from databakkes.be/en/0692655422/giura-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Giura Pharma from Putte, company number BE0692655422, closed financial year 2025 with a result of € 81,021 after tax. For that financial year Giura Pharma recorded a gross margin of € 122,490 and equity of € 461,457. Compared with financial year 2024, the result moved from € 72,134 to € 81,021. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 28, 2026.

What it is worth Growing

€ 461,457

▲ 21% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 81,021

▲ 12% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 87,405

▼ 37% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 442,857.

Debts at end 2025

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 522,713

▲ 81% vs 2024

€ 140,297 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 993

▲ 2% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 9,611

▲ 44% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 106,424 Gross margin 2022: € 106,424 First fiscal year in the series	€ 124,791 Gross margin 2023: € 124,791 ▲ 17% vs 2022 (€ 106,424) Favourable step	€ 109,673 Gross margin 2024: € 109,673 ▼ 12% vs 2023 (€ 124,791) Unfavourable step	€ 122,490 Gross margin 2025: € 122,490 ▲ 12% vs 2024 (€ 109,673) Favourable step	▲ 12%
Profit after taxes	€ 67,682 Profit after taxes 2022: € 67,682 First fiscal year in the series	€ 80,938 Profit after taxes 2023: € 80,938 ▲ 20% vs 2022 (€ 67,682) Favourable step	€ 72,134 Profit after taxes 2024: € 72,134 ▼ 11% vs 2023 (€ 80,938) Unfavourable step	€ 81,021 Profit after taxes 2025: € 81,021 ▲ 12% vs 2024 (€ 72,134) Favourable step	▲ 12%
Equity	€ 227,364 Equity 2022: € 227,364 First fiscal year in the series	€ 308,302 Equity 2023: € 308,302 ▲ 36% vs 2022 (€ 227,364) Favourable step	€ 380,436 Equity 2024: € 380,436 ▲ 23% vs 2023 (€ 308,302) Favourable step	€ 461,457 Equity 2025: € 461,457 ▲ 21% vs 2024 (€ 380,436) Favourable step	▲ 21%
Total debts	€ 390,908 Total debts 2022: € 390,908 First fiscal year in the series	€ 357,141 Total debts 2023: € 357,141 ▼ 9% vs 2022 (€ 390,908) Favourable step	€ 299,910 Total debts 2024: € 299,910 ▼ 16% vs 2023 (€ 357,141) Favourable step	€ 535,385 Total debts 2025: € 535,385 ▲ 79% vs 2024 (€ 299,910) Unfavourable step	▲ 79%
Cash	€ 134,835 Cash 2022: € 134,835 First fiscal year in the series	€ 99,325 Cash 2023: € 99,325 ▼ 26% vs 2022 (€ 134,835) Unfavourable step	€ 137,992 Cash 2024: € 137,992 ▲ 39% vs 2023 (€ 99,325) Favourable step	€ 87,405 Cash 2025: € 87,405 ▼ 37% vs 2024 (€ 137,992) Unfavourable step	▼ 37%
Retained profit	€ 208,764 Retained profit 2022: € 208,764 First fiscal year in the series	€ 289,702 Retained profit 2023: € 289,702 ▲ 39% vs 2022 (€ 208,764) Favourable step	€ 361,836 Retained profit 2024: € 361,836 ▲ 25% vs 2023 (€ 289,702) Favourable step	€ 442,857 Retained profit 2025: € 442,857 ▲ 22% vs 2024 (€ 361,836) Favourable step	▲ 22%
Bank debt	€ 331,349 Bank debt 2022: € 331,349 First fiscal year in the series	€ 310,444 Bank debt 2023: € 310,444 ▼ 6% vs 2022 (€ 331,349) Favourable step	€ 289,233 Bank debt 2024: € 289,233 ▼ 7% vs 2023 (€ 310,444) Favourable step	€ 522,713 Bank debt 2025: € 522,713 ▲ 81% vs 2024 (€ 289,233) Unfavourable step	▲ 81%
Balance sheet total	€ 618,272 Balance sheet total 2022: € 618,272 First fiscal year in the series	€ 665,443 Balance sheet total 2023: € 665,443 ▲ 8% vs 2022 (€ 618,272) Unchanged	€ 680,346 Balance sheet total 2024: € 680,346 ▲ 2% vs 2023 (€ 665,443) Unchanged	€ 996,842 Balance sheet total 2025: € 996,842 ▲ 47% vs 2024 (€ 680,346) Unchanged	▲ 47%

Key figures of Giura Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Giura Pharma?

What happened at Giura Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 28, 2026 New annual accounts for financial year 2025: profit of € 81,021 (▲ 12% vs 2024). Source: NBB ↗
Mar 19, 2018 New establishment in Putte. KBO
Mar 19, 2018 Start of the company according to the CBE. KBO

In short

From € 67,682 profit in 2022 to € 81,021 profit in 2025.

Paid € 145,764 in corporate taxes since 2022.

Best year ever: 2025, with € 81,021 profit.

Original PDFs at the National Bank ↗

Management

Caroline Caenepeel

Giura Pharma

Relst Pharma 50%

Apotrem 50%

Behind Giura Pharma is Caroline Caenepeel. It owns 50% of Relst Pharma and 50% of Apotrem itself.

Directors

According to the 2025 annual accounts

Caroline Caenepeel

Director

Also active at: Relst Pharma, APOTREM

Establishments

Establishment units

Physical locations of this company

Registered office

Heidelaan 25

2580 Putte

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

GIURA

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0692.655.422

VAT number

BE 0692.655.422

Registered office

Heidelaan 25, 2580 Putte

Names & denominations

Giura Pharma

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

19 March 2018

Peppol

Active · Active since 21 Oct 2026

Activities · NACE

Activiteiten van holdings

Holdings

View on CBE Public ↗ Annual accounts (NBB) ↗

Giura Pharma

Financials

What happened to Giura Pharma?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions